The Sublimated Mare Milk Supplement in Hepatitis C
- Conditions
- Hepatitis C
- Interventions
- Dietary Supplement: Mare milk supplementDrug: Standard therapy
- Registration Number
- NCT03669835
- Lead Sponsor
- Asfendiyarov Kazakh National Medical University
- Brief Summary
This clinical trial studies the effect of sublimated mare milk supplement on patients with hepatitis C.
- Detailed Description
Chronic viral hepatitis C is one of the medical, social and economic public health problems throughout the world. In majority of patients with chronic viral hepatitis C, dysbiotic changes are detected in the intestinal tract. Disturbances of microbial equilibrium are associated with the degree of inflammation, morphological changes in the liver, nature of the course and the stage of the disease.
These dysbiotic changes and and associated immune disorders can significantly aggravate the course of immune processes in the liver, converting hepatitis C infection to a chronic disease.
Mare milk is frequently reported for having therapeutic and dietary properties, which are initially associated with a specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, B12, amino acids, enzymes and trace elements, there are low molecular weight peptides, lactalbumins and globulins.
The use of mare milk can contribute to the restoration of impaired functions of damaged organs and tissues, and play the role of an auxiliary pathogenetic therapy, primarily in certain chronic diseases of the digestive system, including chronic viral hepatitis C. Mare milk can also be used as a powder supplement through sublimation process.
In this trial, the effect of this supplement consisting of sublimated mare milk on hepatitis C patients will be evaluated. There will be two parallel groups: Interventional (sublimated mare milk supplement with standard treatment) and Standard treatment group. Differences in laboratory characteristics will be quantitively analyzed between groups.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Patients with verified diagnosis of hepatitis C
- Aged 18 to 65 years
- Normal intestinal microbiota composition (anaerobes-95%, aerobes-5%)
- Normal level of immune system markers in blood (Immunoglobulin M and Immunoglobulin G)
- Decreased levels of phosphatidylethanolamine, phosphatidylserine, phosphatidylcholine, sphingomyelin
- Elevated lysophosphatidylcholine
- Willingness to consent to participate in the study
- Consent to adhere to treatment
- Drug and/or alcohol dependence
- Allergy to dairy products
- People with mental disabilities and/or life-threatening conditions
- Pregnancy and/or lactation
- Lactose intolerance
- Refusal to participate in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dietary supplement and standard therapy. Standard therapy Participants will take a supplement of 1 sachet (20 mg) 3 times/day accompanied with the standard therapy for 1 month. Standard therapy only. Standard therapy Patients would be given standard treatment for 1 month. Dietary supplement and standard therapy. Mare milk supplement Participants will take a supplement of 1 sachet (20 mg) 3 times/day accompanied with the standard therapy for 1 month.
- Primary Outcome Measures
Name Time Method Change in liver function. Baseline, 2 weeks, 4 weeks, 8 weeks Change in liver function will be assessed from biochemical blood results of alanine transaminase and aspartate transaminase.
Change in urine test. Baseline, 2 weeks, 4 weeks, 8 weeks Proportion of patients with deviations from normal range of urine test.
- Secondary Outcome Measures
Name Time Method Changes in gut microbiota composition. Baseline, 2 weeks, 4 weeks, 8 weeks Proportions of aerobic and anaerobic bacteria will be assessed from stool samples using MiSeq Sequencing System.
Changes in degree of liver fibrosis. Baseline, 2 weeks, 4 weeks, 8 weeks Liver fibrosis will be evaluated using transient elastography method.
Intestinal immune status changes. Baseline, 2 weeks, 4 weeks, 8 weeks Level of immune status markers (Immunoglobulin G, Immunoglobulin M) will be detected from blood samples.
Changes in phospholipids spectrum of lymphocyte membranes. Baseline, 2 weeks, 4 weeks, 8 weeks Detection of changes in phospholipids spectrum of lymphocyte membranes (phosphatidylethanolamine, phosphatidylserine, phosphatidylcholine, sphingomyelin, lysophosphatidylcholine) will be performed using the thin-layer chromatography method.
Trial Locations
- Locations (1)
Asfendiyarov Kazakh National Medical University
🇰🇿Almaty, Kazakhstan
Asfendiyarov Kazakh National Medical University🇰🇿Almaty, Kazakhstan